| Hurley, Christine |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
| Hulse, Susan |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV |
|
|
| Recruiting | 2 | 48 | US, RoW | Selgantolimod, Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis B, HIV Infections | 11/26 | 05/27 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission |
|
|
| Recruiting | 2 | 48 | US, RoW | VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy | National Institute of Allergy and Infectious Diseases (NIAID) | Acute HIV Infection | 04/28 | 09/28 | | |
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy |
|
|
| Not yet recruiting | 1 | 30 | US | CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection | National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI) | HIV-1 | 10/26 | 08/27 | | |
